1y57

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
(New page: 200px<br /> <applet load="1y57" size="450" color="white" frame="true" align="right" spinBox="true" caption="1y57, resolution 1.91&Aring;" /> '''Structure of unphos...)
Line 1: Line 1:
-
[[Image:1y57.gif|left|200px]]<br />
+
[[Image:1y57.gif|left|200px]]<br /><applet load="1y57" size="350" color="white" frame="true" align="right" spinBox="true"
-
<applet load="1y57" size="450" color="white" frame="true" align="right" spinBox="true"
+
caption="1y57, resolution 1.91&Aring;" />
caption="1y57, resolution 1.91&Aring;" />
'''Structure of unphosphorylated c-Src in complex with an inhibitor'''<br />
'''Structure of unphosphorylated c-Src in complex with an inhibitor'''<br />
==Overview==
==Overview==
-
The regulation of the activity of Abl and Src family tyrosine kinases is, mediated by intramolecular interactions between the SH3, SH2, and kinase, (SH1) domains. We have determined the crystal structure of an, unphosphorylated form of c-Src in which the SH2 domain is not bound to the, C-terminal tail. This results in an open structure where the kinase domain, adopts an active conformation and the C terminus binds within a, hydrophobic pocket in the C-terminal lobe. NMR binding studies support the, hypothesis that an N-terminal myristate could bind in this pocket, as, observed for Abl, suggesting that c-Src may also be regulated by myristate, binding. In addition, the structure contains a des-methyl analog of the, antileukemia drug imatinib (STI571; Gleevec). This structure reveals why, the drug shows a low affinity for active kinase conformations, contributing to its excellent kinase selectivity profile.
+
The regulation of the activity of Abl and Src family tyrosine kinases is mediated by intramolecular interactions between the SH3, SH2, and kinase (SH1) domains. We have determined the crystal structure of an unphosphorylated form of c-Src in which the SH2 domain is not bound to the C-terminal tail. This results in an open structure where the kinase domain adopts an active conformation and the C terminus binds within a hydrophobic pocket in the C-terminal lobe. NMR binding studies support the hypothesis that an N-terminal myristate could bind in this pocket, as observed for Abl, suggesting that c-Src may also be regulated by myristate binding. In addition, the structure contains a des-methyl analog of the antileukemia drug imatinib (STI571; Gleevec). This structure reveals why the drug shows a low affinity for active kinase conformations, contributing to its excellent kinase selectivity profile.
==Disease==
==Disease==
Line 11: Line 10:
==About this Structure==
==About this Structure==
-
1Y57 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with SO4 and MPZ as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Transferase Transferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 and 2.7.10.2 2.7.10.1 and 2.7.10.2] Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1Y57 OCA].
+
1Y57 is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=SO4:'>SO4</scene> and <scene name='pdbligand=MPZ:'>MPZ</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Active as [http://en.wikipedia.org/wiki/Transferase Transferase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=2.7.10.1 and 2.7.10.2 2.7.10.1 and 2.7.10.2] Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1Y57 OCA].
==Reference==
==Reference==
Line 18: Line 17:
[[Category: Single protein]]
[[Category: Single protein]]
[[Category: Transferase]]
[[Category: Transferase]]
-
[[Category: Cowan-Jacob, S.W.]]
+
[[Category: Cowan-Jacob, S W.]]
[[Category: Fabbro, D.]]
[[Category: Fabbro, D.]]
[[Category: Fendrich, G.]]
[[Category: Fendrich, G.]]
[[Category: Jahnke, W.]]
[[Category: Jahnke, W.]]
[[Category: Liebetanz, J.]]
[[Category: Liebetanz, J.]]
-
[[Category: Manley, P.W.]]
+
[[Category: Manley, P W.]]
[[Category: Meyer, T.]]
[[Category: Meyer, T.]]
[[Category: MPZ]]
[[Category: MPZ]]
Line 31: Line 30:
[[Category: sh3]]
[[Category: sh3]]
-
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 20:15:02 2007''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 16:01:58 2008''

Revision as of 14:02, 21 February 2008


1y57, resolution 1.91Å

Drag the structure with the mouse to rotate

Structure of unphosphorylated c-Src in complex with an inhibitor

Contents

Overview

The regulation of the activity of Abl and Src family tyrosine kinases is mediated by intramolecular interactions between the SH3, SH2, and kinase (SH1) domains. We have determined the crystal structure of an unphosphorylated form of c-Src in which the SH2 domain is not bound to the C-terminal tail. This results in an open structure where the kinase domain adopts an active conformation and the C terminus binds within a hydrophobic pocket in the C-terminal lobe. NMR binding studies support the hypothesis that an N-terminal myristate could bind in this pocket, as observed for Abl, suggesting that c-Src may also be regulated by myristate binding. In addition, the structure contains a des-methyl analog of the antileukemia drug imatinib (STI571; Gleevec). This structure reveals why the drug shows a low affinity for active kinase conformations, contributing to its excellent kinase selectivity profile.

Disease

Known disease associated with this structure: Colon cancer, advanced OMIM:[190090]

About this Structure

1Y57 is a Single protein structure of sequence from Homo sapiens with and as ligands. Active as Transferase, with EC number and 2.7.10.2 2.7.10.1 and 2.7.10.2 Full crystallographic information is available from OCA.

Reference

The crystal structure of a c-Src complex in an active conformation suggests possible steps in c-Src activation., Cowan-Jacob SW, Fendrich G, Manley PW, Jahnke W, Fabbro D, Liebetanz J, Meyer T, Structure. 2005 Jun;13(6):861-71. PMID:15939018

Page seeded by OCA on Thu Feb 21 16:01:58 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools